TY - JOUR
T1 - Acellular dermal matrix as an adjunct material in cleft le Fort i osteotomies
AU - Susarla, Srinivas M.
AU - MacIsaac, Zoe M.
AU - Swanson, Edward
AU - Davidson, Edward
AU - Kumar, Anand
PY - 2017
Y1 - 2017
N2 - Purpose: To evaluate the use of acellular dermal matrix in the management of nasal lining deficiency at the time of Le Fort I osteotomy. Methods: This was a retrospective cohort study of patients with residual/recurrent oronasal fistulae who underwent Le Fort I osteotomy. In instances where there was an inadequate volume of nasal mucosa for tension-free closure or for defects >1cmin width, the acellular dermal matrix was used for augmentation. Demographic and cleft-related factors were recorded. Complications (recurrent fistula, infection, seroma, and wound dehiscence) were recorded. Results: Over the 3-year period, the authors used acellular dermal matrix to augment nasal lining in 8 subjects. The sample's mean age was 18.7 ± 3.1 years; 5 subjects were male. Six patients had bilateral cleft defects. The mean follow-up time was 20.2 ± 3.2 years. There were no episodes of infection, seroma, wound dehiscence, or recurrent fistula. Conclusion: Acellular dermal matrix is a useful adjunct for managing nasal lining deficiency at the time of Le Fort I osteotomy. There were no episodes of bone graft extrusion, infection, tooth loss, or bone graft loss. The Enemark scores improved significantly across both subsets (P <0.001). There was 1 recurrent fistula in the allograft bone alone group. Residual alveolar clefts and oronasal fistulae can be successfully managed at the time of Le Fort I osteotomy using allograft bone and acellular dermal matrix.
AB - Purpose: To evaluate the use of acellular dermal matrix in the management of nasal lining deficiency at the time of Le Fort I osteotomy. Methods: This was a retrospective cohort study of patients with residual/recurrent oronasal fistulae who underwent Le Fort I osteotomy. In instances where there was an inadequate volume of nasal mucosa for tension-free closure or for defects >1cmin width, the acellular dermal matrix was used for augmentation. Demographic and cleft-related factors were recorded. Complications (recurrent fistula, infection, seroma, and wound dehiscence) were recorded. Results: Over the 3-year period, the authors used acellular dermal matrix to augment nasal lining in 8 subjects. The sample's mean age was 18.7 ± 3.1 years; 5 subjects were male. Six patients had bilateral cleft defects. The mean follow-up time was 20.2 ± 3.2 years. There were no episodes of infection, seroma, wound dehiscence, or recurrent fistula. Conclusion: Acellular dermal matrix is a useful adjunct for managing nasal lining deficiency at the time of Le Fort I osteotomy. There were no episodes of bone graft extrusion, infection, tooth loss, or bone graft loss. The Enemark scores improved significantly across both subsets (P <0.001). There was 1 recurrent fistula in the allograft bone alone group. Residual alveolar clefts and oronasal fistulae can be successfully managed at the time of Le Fort I osteotomy using allograft bone and acellular dermal matrix.
KW - Cleft lip and palate
KW - Cleft orthognathic surgery
KW - Oronasal fistula
UR - http://www.scopus.com/inward/record.url?scp=85006356161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006356161&partnerID=8YFLogxK
U2 - 10.1097/SCS.0000000000003308
DO - 10.1097/SCS.0000000000003308
M3 - Article
C2 - 27997450
AN - SCOPUS:85006356161
SN - 1049-2275
VL - 28
SP - 225
EP - 226
JO - Journal of Craniofacial Surgery
JF - Journal of Craniofacial Surgery
IS - 1
ER -